MAGE-A4-TCRS

DE602020051589T2Active Publication Date: 2025-05-21MEDIGENE IMMUNOTHERAPIES GMBH +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
DE602020051589
Authority / Receiving Office
DE · DE
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-03-27
Filing Date
2020-03-27
Publication Date
2025-05-21
Estimated Expiration
2040-03-27

AI Technical Summary

Technical Problem

Current cancer treatments using adoptive cell therapy face challenges in isolating and characterizing tumor-specific T cells, which are time-consuming and often yield low-avidity cells, limiting their effectiveness in targeting cancer cells, particularly those expressing MAGE-A4 antigens.

Method used

Development of isolated T cell receptors (TCRs) specific for MAGE-A4, which recognize the amino acid sequence GVYDGREHTV presented by HLA-A*02:01 molecules, enabling efficient targeting and recognition of MAGE-A4-positive cancer cells with enhanced avidity and specificity.

Benefits of technology

The MAGE-A4-specific TCRs demonstrate significantly higher IFN-g secretion and cytotoxic activity against MAGE-A4-positive tumor cells while sparing normal cells, indicating improved therapeutic efficacy and specificity in cancer immunotherapy.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to an isolated T cell receptor (TCR) specific for MAGE-A4 and a polypeptide comprising a functional portion of the TCR. Further implicated are a multivalent TCR complex, a nucleic acid encoding a TCR, a cell expressing the TCR and a pharmaceutical composition comprising the TCR. The invention also refers to the TCR for use as a medicament, in particular to the TCR for use in the treatment of cancer.
Need to check novelty before this filing date? Find Prior Art